TRIM21 and interstitial lung disease: Anti-Ro52 positivity (45.8% overall) emerged as a notable predictor of ILD (odds ratio [OR]: 22.5, 95% confidence interval [CI]: 2.10-240.48; <i>p</i> = 0.0045), being present in 71.4% of affected patients.